This article is more than 5 years old. Information may no longer be current.
Trabecular bypass implant shows stable results in glaucoma patients at 4 years
Click Here to Manage Email Alerts
PARIS — The iStent glaucoma implant showed stable IOP reduction in a long-term prospective study.
The iStent implant (Glaukos) is a trabecular bypass that is inserted ab interno through a small temporal clear corneal incision to increase trabecular outflow. It is mostly used in association with cataract surgery.
"We used this implant in 22 eyes of 22 patients with [primary open-angle glaucoma] (72%), pseudoexfoliation syndrome (18%) or [pigment dispersion syndrome] (10%). Intraocular pressure was equal or higher than 18 mm Hg, requiring at least one glaucoma medication per day. All patients had a concurrent diagnosis of cataract requiring phacoemulsification surgery," Pedro Arriola, MD, said here at the meeting of the European Society of Cataract and Refractive Surgeons.
The implantation of the iStent was performed after cataract extraction, under topical anesthesia, and resulted in a significant mean IOP reduction of 3.4 mm Hg. The mean number of medications used was reduced by half.
"These results are stable at 4 years. No complication related to the stent was reported," Dr. Arriola said.